B-cell depletion with unconjugated CD20 monoclonal antibody (mAb) is used to treat rheumatoid arthritis and other autoimmune diseases. CD20-targeted immunotherapy depletes mature B cells through ...

The 61 st annual meeting of the American Society of Hematology (ASH) conducted in 2019 presented bi-specific antibodies that target CD20 on the surface of B cells and CD3 on the surface of T cells ...

Rituximab, a monoclonal antibody directed against the CD20 molecule found on pre-B cells and mature B cells (but not on plasma cells), was introduced in the late 1990s for the treatment of non ...

Micrograph of a diffuse large B cell lymphoma, AbbVie and partner Genmab have FDA approval for the lead drug in their $3.9 billion cancer partnership, with bispecific antibody Epkinly now cleared ...

Ofatumumab shows good efficacy in conditions with low CD20 expression and is approved ... higher antitumor activity in refractory B-cell non-Hodgkin lymphoma. CMC-544 has high efficacy in ...

ICP-B02 binds to CD20 on the tumor cells and CD3 on the T ... particularly in patients with follicular lymphoma (FL) and diffuse large B-cell lymphoma (DLBCL). Based on the encouraging results ...